{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Status:
Investigational
Source:
NCT03217825: Phase 2 Interventional Completed Hypertension
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Rostafuroxin (PST 2238) is a digitoxygenin derivative, which selectively displaces ouabain from the Na ,K -ATPase receptor. PST 2238, at concentrations up to 10−4 M, did not show any significant interaction with a- and b-adrenergic, D1, D2, D3, 5-HT1, 5-HT2, H1, H2, M1, M2, A1, A2, Ca2 , Na , or K channel–associated receptors, AT1, AT2, ETa, ETb, GABA, thromboxane, vasopressin, angiotensin II, or the steorid-hormone receptors (androgen, progestogen, estrogen and mineralocorticoid), confirming that PST 2238 is specific for Na ,K -ATPase. Rostafuroxin has been developed in an attempt to unravel the contribution of mutated adducin and endogenous ouabain in the pathogenesis of hypertension. The compound lowered blood pressure in Milan hypertensive rats and humans. Rostafuroxine had been in phase II clinical trials for the treatment of hypertension. Following adverse events in Rostafuroxin group were described: dizziness, headache, upper respiratory tract infections, high blood pressure.
Status:
Investigational
Source:
USAN:LEVALBUTEROL SULFATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:MECLORISONE DIBUTYRATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mebolazine is an androgenic anabolic steroid.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Mantabegron is an adamantane derivative with β3-adrenoreceptor agonist activity.
Status:
Investigational
Source:
INN:zoleprodolol [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Zoleprodolol was developed as an adrenoreceptor antagonist. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Stevaladil is a pregnanediol derivative patented by Shionogi & Co., Ltd. as antiparasitic agent
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
Ganglefene is a coronary vasodilator. This n-cholinoblocker was originally studied for its effects on coronary circulation in angina pectoris. Animal studies have also shown shortened recovery period of motor functions after ganglefene administration. One rodent study showed that modulation of the n-cholinergic system by ganglefene in the developing fetal brain leads to changes in the quantitative and qualitative characteristics of elements of sexual behavior in pubescent offspring.
Status:
Investigational
Source:
NCT04390295: Phase 3 Interventional Unknown status Type 2 Diabetes Mellitus
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Tropapride is dopamine D2 receptor antagonist, which potential high antipsychotic activity has been clearly shown in biochemical and pharmacological tests.
